Oral peptides are studied not because the gut absorbs peptides well — it absorbs them very poorly — but because some research questions only need the peptide to reach the gut lumen, and because capsule and troche formats sidestep the enteral barrier in different ways. Unmodified peptides swallowed as a solution show systemic bioavailability typically below 1% in published work, so any study design using an oral format has to state explicitly whether it is asking a local question or a systemic one. This guide explains what destroys peptides in the gastrointestinal tract, how enteric coating, salt forms and sublingual troches change the picture, and how to reason about a research design that uses an oral format. It describes laboratory reference material for research use only.
Four barriers between a capsule and the bloodstream
- Gastric acid. Stomach pH of roughly 1.5–3.5 catalyses hydrolysis of the peptide backbone and denatures secondary structure. Acid-labile sequences can lose most of their integrity within an hour of gastric residence.
- Luminal proteases. Pepsin in the stomach, then pancreatic trypsin, chymotrypsin and carboxypeptidases in the duodenum, exist precisely to cut peptide bonds. A researcher's peptide is indistinguishable from dietary protein to these enzymes.
- Brush-border peptidases and epithelial transit. Whatever survives the lumen meets aminopeptidases anchored to the enterocyte surface, and then has to cross an epithelium whose tight junctions exclude hydrophilic molecules well below peptide size.
- Hepatic first pass. Absorbed material drains into the portal vein and passes through the liver before reaching systemic circulation.
The compounded effect is why bioavailability for an unmodified oral peptide is measured in fractions of a percent. Semaglutide's oral tablet is the instructive counter-example: it required a permeation enhancer (SNAC) co-formulated at roughly 100 times the peptide mass to reach a reported bioavailability of about 0.4–1%, and it is a prescription medicine, not a research-grade preparation.
Why oral peptides are still useful: local versus systemic
Several of the most-requested oral research peptides are studied for effects in the gastrointestinal tract, not beyond it. BPC-157 capsules and KPV capsules are the clearest cases. BPC-157 was originally isolated as a fragment of a protein found in human gastric juice, and much of the rodent literature examines gastrointestinal mucosal models where the compartment of interest is the lumen and the mucosa lining it. KPV, the C-terminal tripeptide of α-MSH, has been examined in colitis models where the epithelium itself is the target tissue.
For those designs, low systemic absorption is not a defect — it is closer to a feature, because it concentrates exposure where the question lies and limits confounding systemic signal. A study asking whether a peptide modulates a tendon or a receptor in the brain cannot use the same reasoning, and an oral format is the wrong tool for it. The comparison between formats for one molecule is worked through in BPC-157 capsules vs BPC-157.
How the formats differ
| Format | Route of release | Systemic bioavailability (published range) | Best-suited research question |
|---|---|---|---|
| Plain capsule | Dissolves in stomach | Typically <1%, often unmeasurable | Gastric-compartment models |
| Enteric-coated capsule | Coating survives pH <5, releases in duodenum | <1%, but far more intact peptide reaches the intestine | Intestinal and colonic mucosal models |
| Arginate salt capsule | Stomach, with improved aqueous stability | <1% systemic; better luminal survival reported | Gastric models where the free-base salt degrades too fast |
| Sublingual troche | Buccal/sublingual mucosa, partly swallowed | Low single digits for small peptides; bypasses first pass for the absorbed fraction | Small sequences under roughly 1,000 Da needing some systemic exposure |
| Dissolving strip | Buccal mucosa, rapid dissolution | Similar to troche, shorter contact time | Small molecules and cofactors rather than large peptides |
| Nasal spray | Nasal epithelium | A few percent to low tens of percent for small peptides | See peptide nasal sprays |
| Lyophilized vial, reconstituted | Parenteral reference standard | Reference point, near-complete | Any design needing known systemic exposure |
Why troches are not just slow capsules
A sublingual troche is designed to dissolve against the mucosa under the tongue, where the epithelium is thin, non-keratinised and drained by veins that empty into the systemic circulation rather than the portal vein. The absorbed fraction therefore skips hepatic first pass entirely. The catch is that the same molecular-weight ceiling applies as for nasal delivery — absorption falls steeply above roughly 1,000 Da — and that saliva production continuously carries dissolved material toward the oesophagus, so the swallowed fraction re-enters the gastrointestinal route and its barriers. Oxytocin troches (1,007 Da) sit right at that ceiling; AOD-9604 troches (1,815 Da) sit above it, and the published rationale there leans on local and buccal exposure rather than on efficient systemic uptake.
Worked example: what a capsule figure actually means
Suppose a research protocol calls for a capsule containing 500 mcg of peptide.
- Systemic equivalent at 1% bioavailability. 500 mcg × 0.01 = 5 mcg reaching circulation intact. That is the number to compare against a parenteral reference arm, not the 500 mcg on the label.
- At 0.3%, a figure closer to what unmodified peptides report without a permeation enhancer: 500 × 0.003 = 1.5 mcg.
- Luminal concentration instead. If the question is local, the relevant figure is different: 500 mcg released into an estimated 250 mL of intestinal fluid gives 2 mcg/mL, or roughly 1.4 µM for a 1,420 Da peptide such as BPC-157. That is a concentration a cell-culture experiment can be designed around.
- Compare against a vial. A 5 mg vial reconstituted to 2.5 mg/mL supplies 500 mcg in 0.2 mL of solution with essentially none of it lost to proteolysis — a 100- to 300-fold difference in delivered systemic mass for the same nominal amount.
Stating which of these four numbers a protocol is using removes most of the ambiguity that oral peptide studies suffer from.
Handling and storage
- Capsules and troches are solid presentations with excipients; they are not reconstituted and should not be opened and dissolved unless the study explicitly calls for it, because the coating or matrix is part of the specification.
- Store cool, dry and dark. Humidity is the main enemy: gelatin and HPMC shells soften and stick, and troche bases soften above roughly 25 °C.
- Do not refrigerate capsules in an unsealed container — condensation on removal is worse than ambient storage in a desiccated jar.
- Lot COAs for oral formats should report the peptide content per unit as well as the peptide's own purity; ask for both, as covered in how to read a COA.
Common mistakes
- Comparing an oral label mass with a parenteral one. They are not the same quantity and differ by two to three orders of magnitude in systemic terms.
- Assuming enteric coating raises systemic bioavailability. It raises the amount of intact peptide reaching the intestine; the epithelial barrier and first-pass metabolism are unchanged.
- Using a large peptide in a troche and describing the design as sublingual delivery when most of the material is being swallowed.
- Opening capsules to reconstitute the contents. Capsule fill contains excipients that are not characterised for solution work, and the resulting concentration is unknown. Use a lyophilized vial when a known-concentration solution is required.
The full oral range sits in the peptide capsules and oral collection.